Skip to content

Trial · Interventional

TerminatedPhase 3Results postedRegistry data

Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency

Short name IGHD

Overview

Status
Terminated
Phase
Phase 3
Enrollment
9 participants (actual)
Sponsor
Pfizer · Industry
Design
Randomized · Double masking
Countries
1 country

Germany

Start
May 2008
Primary completion
Oct 2008
Completion
Oct 2008
First posted
7 Mar 2008 (estimated)
Last update posted
4 Mar 2013 (estimated)
Conditions
Growth Hormone Deficiency

Timeline

1 trial · 1 stopped early · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20082009
  1. Ph 3

    IGHD

    NCT00630487

    May 2008 to Oct 2008

    Terminated

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The study will investigate the effect on growth hormone replacement in patients with isolated growth hormone deficiency on body composition, especially visceral fat mass.

Interventions

  • PlaceboDrug
  • SomatropinDrug

Arms2

  • Placebo comparator

    Placebo

  • Active comparator

    Verum

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI)

    Time frame · Baseline, 52 weeks

    Registry description

    Fat measurements carried out with the subjects lying in a supine position in a MRI scanner. Measurements of regional body fat obtained between the level of the coccygeal bone and the 2nd or 3rd lumbar vertebra.

Secondary outcomes(14)
  1. Change in Visceral Fat Mass in Subgroups

    Time frame · Baseline, 52 weeks, 78 weeks

    Registry description

    Change in visceral fat mass in subgroups. Subgroup 1: isolated GHD due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).

  2. Change From Baseline in Anthropometric Parameters (Height)

    Time frame · Baseline, 52 weeks, 78 weeks

  3. Change From Baseline in Anthropometric Parameters (Weight)

    Time frame · Baseline, 52 weeks, 78 weeks

  4. Change From Baseline in Anthropometric Parameters (Waist Circumference)

    Time frame · Baseline, 52 weeks, 78 weeks

  5. Change From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT])

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Alertness: software-based neuropsychological assessment for response time and errors. Memory: analysis of learning and retention using 5-trial presentation of 15-word list (A), single presentation of interference list (B), 2 postinterference recall trials - 1 immediate, 1 delayed - and recognition of the target words with distractors (C). Performance variables were immediate word span under overload conditions, final acquisition level, amount learned in 5 trials, interference, delayed recall, and recognition (implicit learning).

  6. Change From Baseline in Blood Pressure

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Blood pressure was measured seated, the subject's arm supported at the level of the heart, and recorded to the nearest mm Hg. The same arm (preferably the dominant arm) was used throughout the trial. The subject was seated for 5 minutes before the blood pressure was obtained. Use of an automated device could have been used for measuring blood pressure.

  7. Change From Baseline in Heart Rate

    Time frame · Baseline, Week 52, Week 78

    Registry description

    The use of an automated device for measuring pulse rate was acceptable, although, when done manually, pulse rate was measured in the brachial/radial artery for at least 30 seconds.

  8. Change in Executive Function and Memory in Subgroups

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Change in executive function and memory in subgroups. Subgroup 1: isolated Growth Hormone Deficiency (GHD)due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Median reaction time, the total number of errors, the number of omissions and the number of false positive reactions.

  9. Change From Baseline in Safety Laboratory Assessments

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Prespecified safety laboratory assessments evaluated for change or no change from baseline. Possible responses were Yes/No.

  10. Change From Baseline in Homeostasis Model Assessment (HOMA)-Index

    Time frame · Baseline, Week 52, Week 78

    Registry description

    HOMA index is calculated by 1 of 2 methods: HOMA-Index = fasting insulin measured in microunits per milliliter (µU/ml) times fasting glucose measured in milligrams per deciliter mg/dl) divided by 405 or HOMA-Index = fasting insulin (µU/ml) times fasting glucose measured in millimoles per liter (mmol/l) divided by 22.5.

  11. Change From Baseline in Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Participant self administered questionnaire consisting of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life.

  12. Change From Baseline in Short Form (36) Health Survey (SF36)

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Participant self administered questionnaire that measures each of the following eight health concepts: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); Mental Health (MH) as well as a reported Health Transition item (HT). Scale range 0 to 100, higher scores indicate a better health-related quality of life.

  13. Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D)

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Participant self-administered questionnaire EQ-5D, a 2 part generic health status instrument. The first part consists of 5 descriptors of current health state: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Scores are assigned on a three-level scale (1= no problem, 2= some problem, 3= extreme problem). The second part was an overall rating of the participant's current health state using a 20 cm Visual Analogue Scale (EQ-VAS) with endpoints labelled 'best imaginable health state' and 'worst imaginable health state'.

  14. Change From Baseline in Cardiovascular Risk Factors

    Time frame · Baseline, Week 52, Week 78

    Registry description

    Change in values of laboratory tests indicative of possible cardiovascular risk factors: high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, N-terminal pro brain natriuretic peptide)

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcome· Baseline, 52 weeks

Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI)

GroupValue
Placebonot posted
Somatropinnot posted
Secondary and other outcome results(7)
Secondary outcome· Baseline, 52 weeks, 78 weeks

Change in Visceral Fat Mass in Subgroups

GroupValue
Placebonot posted
Somatropinnot posted
Secondary outcome· Baseline, 52 weeks, 78 weeks

Change From Baseline in Anthropometric Parameters (Height)

GroupValue
Placebonot posted
Somatropinnot posted
Secondary outcome· Baseline, 52 weeks, 78 weeks

Change From Baseline in Anthropometric Parameters (Weight)

GroupValue
Placebonot posted
Somatropinnot posted
Secondary outcome· Baseline, 52 weeks, 78 weeks

Change From Baseline in Anthropometric Parameters (Waist Circumference)

GroupValue
Placebonot posted
Somatropinnot posted
Secondary outcome· Baseline, Week 52, Week 78

Change From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT])

GroupValue
Placebonot posted
Somatropinnot posted
Secondary outcome· Baseline, Week 52, Week 78

Change From Baseline in Blood Pressure

GroupValue
Placebonot posted
Somatropinnot posted
Secondary outcome· Baseline, Week 52, Week 78

Change From Baseline in Heart Rate

GroupValue
Placebonot posted
Somatropinnot posted

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Placebo–0 / 00 / 0
SomatropinGrowth hormone (GH) replacement therapy in fixed dose regimen according to age and gender: males less than or equal to 45 years receive 0.4 milligrams (mg) and females receive 0.5mg. Males greater than 45 years receive 0.2 mg and females receive 0.3 mg.–0 / 00 / 0

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 65 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Males and females between 18 and 65 years of age * Isolated growth hormone deficiency Exclusion Criteria: * Isolated growth hormone deficiency by childhood onset * Diabetes mellitus type 1 or 2

PepBank is a research reference. Talk to a doctor before you use any peptide.